NetScientific PLC ProAxsis presents data to validate its immunoassay (2866H)
30 Novembro 2015 - 5:00AM
UK Regulatory
TIDMNSCI
RNS Number : 2866H
NetScientific PLC
30 November 2015
NetScientific plc
ProAxsis presents new data to validate its ProteaseTag(TM)
Active NE Immunoassay in chronic obstructive pulmonary disease
patients
London, UK - 30 November 2015 - NetScientific plc's
("NetScientific" or the "Group", AIM: NSCI) portfolio company,
ProAxsis, a medical diagnostics spin-out from Queen's University
Belfast, will present new data that validates the use of its
ProteaseTag(TM) Active Neutrophil Elastase (NE) Immunoassay in
chronic obstructive pulmonary disease (COPD) patients for the first
time.
The results will be presented in the Best of Science Advances
session at 2pm on the 3 December during the British Thoracic
Society Winter meeting, taking place over 2-4 December in
London.
ProAxsis's rapid and easy-to-use ProteaseTags(TM) test uses
smart molecules to trap active protease biomarkers of diseases
within a complex biological sample and enable a visual readout of
its presence. This test measures Neutrophil Elastase, an important
drug target and leading indicator of infection in patients with
cystic fibrosis and COPD. The technology provides a unique tool to
identify and quantify active protease biomarkers to assist in the
clinical validation of new therapeutics.
ProAxsis has previously presented data on the use of its
immunoassay in both adult and paediatric cystic fibrosis patients,
but this is the first time that the immunoassay has been validated
for use with COPD patients. The COPD market for NE testing is
substantially larger than that for cystic fibrosis. Currently,
there are around 3 million people in the UK with COPD and
approximately 2 million are undiagnosed, this has created a need
for better diagnostic tests to help diagnose COPD and ensure
patients are identified and treated promptly.
Dr James Chalmers from the Department of Respiratory Medicine at
Ninewells Hospital in Dundee, who co-authored the work, said: "This
study shows that the ProteaseTag(TM) Active NE Immunoassay can be
used as a specific tool to measure NE activity in COPD samples. The
results clearly highlighted the elevated levels of NE seen in
sputum samples from COPD patients suffering from an
exacerbation."
Dr David Ribeiro, CEO of ProAxsis, said: "These results are
important as they demonstrate the potential value of our
ProteaseTag(TM) Active NE Immunoassay within COPD. The test is
already commercially available for researchers in the respiratory
field, and this validation further broadens the number of areas
that researchers can use it for."
- Ends -
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment.
For more information, please visit the website at
www.netscientific.net.
About ProAxsis
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of
diseases. The rapid and easy-to-use tests incorporate patented
ProteaseTags(TM); smart molecules which trap an active protease
within a complex biological sample and enable a visual readout of
its presence. ProAxsis also offers customers a highly experienced
team that can provide clinical research services in regard to the
specific measurement of active proteases within clinical samples as
well as target validation.
The company was named one of Northern Ireland's most promising
companies in 2013. It is the only company in Northern Ireland, and
one of only a few in the UK, to have secured a prestigious Horizon
2020 SME Instrument Award. ProAxsis has also been highlighted as a
success story in Medical Research Council's 2014/15 Outputs,
Outcomes and Impact research report.
ProAxsis is part of the NetScientific group and is one of the
group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University. For more
information, please visit: www.proaxsis.com.
Contact Details
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Peter Thoms, CFO
Investec (NOMAD and broker) Tel: +44 (0)20 7597
Gary Clarence / Daniel 4000
Adams
Instinctif Partners Tel: +44 (0)20 7457
Melanie Toyne-Sewell / 2020 Email: netscientific@instinctif.com
Jayne Crook / Rosanna
Forrest
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZMMZMLLLGKZM
(END) Dow Jones Newswires
November 30, 2015 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024